Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2010 1
2011 2
2012 1
2014 2
2020 1
2023 1
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "EGFR-related lung cancer"
Page 1
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, Hayashi H; MARIPOSA Investigators. Cho BC, et al. N Engl J Med. 2024 Oct 24;391(16):1486-1498. doi: 10.1056/NEJMoa2403614. Epub 2024 Jun 26. N Engl J Med. 2024. PMID: 38924756 Clinical Trial.
BACKGROUND: Amivantamab plus lazertinib (amivantamab-lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung c …
BACKGROUND: Amivantamab plus lazertinib (amivantamab-lazertinib) has shown clinically meaningful and durable antitumor activity in patients …
EGFR genomic alterations in cancer: prognostic and predictive values.
Bronte G, Terrasi M, Rizzo S, Sivestris N, Ficorella C, Cajozzo M, Di Gaudio F, Gulotta G, Siragusa S, Gebbia N, Russo A. Bronte G, et al. Front Biosci (Elite Ed). 2011 Jun 1;3(3):879-87. doi: 10.2741/e296. Front Biosci (Elite Ed). 2011. PMID: 21622099 Free article. Review.
Many data involving EGFR protein expression are now available for the choice of anti-EGFR monoclonal antibodies in colorectal cancer and with regard to EGFR gene mutations for the choice of tyrosine kinase inhibitors in lung cancer. Other EGFR-relat …
Many data involving EGFR protein expression are now available for the choice of anti-EGFR monoclonal antibodies in colorectal cancer …
The emerging role of noncoding RNAs in the EGFR signaling pathway in lung cancer.
Mohan S, Hakami MA, Dailah HG, Khalid A, Najmi A, Zoghebi K, Halawi MA. Mohan S, et al. Pathol Res Pract. 2024 Jan;253:155016. doi: 10.1016/j.prp.2023.155016. Epub 2023 Dec 5. Pathol Res Pract. 2024. PMID: 38070221 Review.
The clinical implications of ncRNAs in EGFR-driven lung cancer are substantial. These molecules exhibit diagnostic potential as robust biomarkers for early cancer detection and personalized treatment. ...This review explores the increasing evidence supporting …
The clinical implications of ncRNAs in EGFR-driven lung cancer are substantial. These molecules exhibit diagnostic potential a …
Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer.
Wang Y, Hu C, Yu H, Hu J, Zhou Z, Fu N, Huang X, Kong F, Wang W, Liu J. Wang Y, et al. Lung Cancer. 2024 Mar;189:107495. doi: 10.1016/j.lungcan.2024.107495. Epub 2024 Jan 28. Lung Cancer. 2024. PMID: 38335691
Non-small cell lung cancers (NSCLC) account for 85 % of total lung cancers. Mutation in EGFRdrives the progress of NSCLSs with high mortality rate. ...We also explored the oncogenic feature of single R776L mutation by Ba/F3 isogenic cells and found that, EGFR R776L …
Non-small cell lung cancers (NSCLC) account for 85 % of total lung cancers. Mutation in EGFRdrives the progress of NSCLSs with …
Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
Chung CT, Yeh KC, Lee CH, Chen YY, Ho PJ, Chang KY, Chen CH, Lai YK, Chen CT. Chung CT, et al. Pharmacol Res. 2020 Nov;161:105183. doi: 10.1016/j.phrs.2020.105183. Epub 2020 Sep 5. Pharmacol Res. 2020. PMID: 32896579 Free article.
Non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related death worldwide. NSCLC patients with overexpressed or mutated epidermal growth factor receptor (EGFR) related to disease progression are treated with EGFR-tyrosine kinase in …
Non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related death worldwide. NSCLC patients with overexpres …
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M. Schneider CP, et al. J Thorac Oncol. 2008 Dec;3(12):1446-53. doi: 10.1097/JTO.0b013e31818ddcaa. J Thorac Oncol. 2008. PMID: 19057271 Free article. Clinical Trial.
INTRODUCTION: Relationships between clinical outcomes and epidermal growth factor receptor (EGFR)-related tumor markers were investigated in patients with advanced non-small cell lung cancer. METHODS: Patients with stage IIIB/IV non-small cell lung …
INTRODUCTION: Relationships between clinical outcomes and epidermal growth factor receptor (EGFR)-related tumor markers were i …
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR. Khambata-Ford S, et al. J Clin Oncol. 2010 Feb 20;28(6):918-27. doi: 10.1200/JCO.2009.25.2890. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100958 Clinical Trial.
PURPOSE The anti-epidermal growth factor receptor (EGFR) antibody cetuximab is efficacious in multiple tumor types. Patient selection with markers predictive of benefit may enhance its therapeutic index. This retrospective, correlative analysis of the phase III trial BMS09 …
PURPOSE The anti-epidermal growth factor receptor (EGFR) antibody cetuximab is efficacious in multiple tumor types. Patient selection with m …
Value of multi-center (18)F-FDG PET/CT radiomics in predicting EGFR mutation status in lung adenocarcinoma.
Zuo Y, Liu L, Chang C, Yan H, Wang L, Sun D, Ruan M, Lei B, Xia X, Xie W, Song S, Huang G. Zuo Y, et al. Med Phys. 2024 Jul;51(7):4872-4887. doi: 10.1002/mp.16947. Epub 2024 Jan 29. Med Phys. 2024. PMID: 38285641
The validation of multi-center data, model visualization, and interpretation are significantly important for the management, application and trust of machine learning predictive models. However, few EGFR-related research involved model visualization and inter …
The validation of multi-center data, model visualization, and interpretation are significantly important for the management, application and …
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.
Milella M, Nuzzo C, Bria E, Sperduti I, Visca P, Buttitta F, Antoniani B, Merola R, Gelibter A, Cuppone F, D'Alicandro V, Ceribelli A, Rinaldi M, Cianciulli A, Felicioni L, Malatesta S, Marchetti A, Mottolese M, Cognetti F. Milella M, et al. J Thorac Oncol. 2012 Apr;7(4):672-80. doi: 10.1097/JTO.0b013e31824a8bde. J Thorac Oncol. 2012. PMID: 22425916 Free article. Clinical Trial.
INTRODUCTION: The optimal use of epidermal growth factor receptor (EGFR)-related molecular markers to prospectively identify tyrosine kinase inhibitor (TKI)-sensitive patients, particularly after a previous chemotherapy treatment, is currently under debate. ...CONCL …
INTRODUCTION: The optimal use of epidermal growth factor receptor (EGFR)-related molecular markers to prospectively identify t …
EfficientNet-Based System for Detecting EGFR-Mutant Status and Predicting Prognosis of Tyrosine Kinase Inhibitors in Patients with NSCLC.
Xu N, Wang J, Dai G, Lu T, Li S, Deng K, Song J. Xu N, et al. J Imaging Inform Med. 2024 Jun;37(3):1086-1099. doi: 10.1007/s10278-024-01022-z. Epub 2024 Feb 15. J Imaging Inform Med. 2024. PMID: 38361006 Free PMC article.
We aimed to develop and validate a deep learning-based system using pre-therapy computed tomography (CT) images to detect epidermal growth factor receptor (EGFR)-mutant status in patients with non-small cell lung cancer (NSCLC) and predict the prognosis of ad …
We aimed to develop and validate a deep learning-based system using pre-therapy computed tomography (CT) images to detect epidermal growth f …
14 results